HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus.

Abstract
Transcatheter arterial chemoembolization (TACE) is used in the treatment of hepatocellular carcinoma; however, it has limited effect on portal vein tumor thrombus (PVTT). The purpose of this study was to assess the feasibility and efficacy of radiotherapy targeting the PVTT after TACE for the tumor in the hepatic parenchyma. TACE was performed using epirubicin hydrochloride, iodized poppy seed oil, and gelatin sponge particles. Radiotherapy was performed targeting the PVTT to a total dose of 50 Gy in 25 fractions during 5 weeks. Twenty consecutive patients were treated with this combined treatment. Sixteen of 20 patients could complete the planned radiotherapy. Partial response was observed in 10, no change in 4, and progression in 6. The response rate was 50% (95% CI 28-72%). The 1-year overall survival rate was 25% (95% CI 6-44%), and the median survival time was 5.3 months. It was difficult to determine the late toxicities because of disease progression and additional TACE, and only one patient died without disease progression. Radiotherapy after TACE is feasible for patients with hepatocellular carcinoma and PVTT. The survival figure, however, is still dismal, and further investigation is needed to establish the best combination of treatment modalities.
AuthorsSatoshi Ishikura, Takashi Ogino, Junji Furuse, Mitsuo Satake, Satoshi Baba, Mitsuhiko Kawashima, Keiji Nihei, Yoshinori Ito, Yasushi Maru, Hiroshi Ikeda
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 25 Issue 2 Pg. 189-93 (Apr 2002) ISSN: 0277-3732 [Print] United States
PMID11943901 (Publication Type: Clinical Trial, Journal Article)
Topics
  • Adult
  • Aged
  • Carcinoma, Hepatocellular (radiotherapy, therapy)
  • Chemoembolization, Therapeutic
  • Combined Modality Therapy
  • Female
  • Humans
  • Liver Neoplasms (radiotherapy, therapy)
  • Male
  • Middle Aged
  • Neoplastic Cells, Circulating (radiation effects)
  • Portal Vein
  • Radiotherapy Dosage

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: